Professor Harald A. Stenmark, head of the "Cellular membrane dynamics" research group at the Department of Molecular Cell Biology at the Institute for Cancer Research, has been given the prestigious University of Oslo Research Research Award for 2018.
In their statement the prize committee wishes to acknowledge one of the University's most prominent researchers in cancer research and cell biology, who has built an internationally renowned research environment that delivers innovative and original research helping to put the University of Oslo on the world map.
The research award will be distributed during the annual UiO party on September 2nd. Prizes for education, communication and innovation will also be given out during this event, each of the four awards amounting to 250.000 NOK.
Dag Berild, head of the "Study group for rational antibiotic use" at the Department of Infectious Diseases at the Division of Medicine was appointed "Researcher of the Month" for July 2018 by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF).
Antibiotic resistance is now one of the biggest threats to public health in the world. Dag Berild was among the first to warn against the wrong use of antibiotics. Berild's research activities is presented in a feature article published on the home page of Helse Sør-Øst.
The "DoMore!" project headed by Håvard E. Danielsen, director of the Institute for Cancer Genetics and Informatics, was recently presented in a feature article in the major national Norwegian newspaper VG.
By examining 20.000 cancer tumor samples from more than 7000 patients and using artificial intelligence the scientists look for patterns that may say something about a patient's prognosis. They focus on the three most common forms of cancer - lung, colorectal and prostate cancer. Results from the project har recently been published in Lancet Oncology (journal impact factor 36.4).
The DoMore! project was selected in 2016 as one of the Norwegian Research Council’s Lighthouse projects to solve large societal challenges using cutting-edge technologym and will run until 2021.
Postdoctor Andreas M. Hoff in the Skotheim group at the Department of Molecular Oncology spent a year of his postdoc in the lab of Matthew Meyerson at the Broad Institute and Dana Farber Cancer Institute, Boston, USA. As shared first-author, he publishes together with his colleagues at the Meyerson lab in the prestigous journal Cell (impact factor 30).
Therese Seierstad from Mona-Elisabeth Revheim's "Functional and Molecular Imaging" research group at the Division of Radiology and Nuclear Medicine was appointed "Researcher of the Month" for June 2018 by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). Her research is mostly focused on prostate cancer and breast cancer. As head of research at the division she is also involved in research projects not directly related to cancer treatment. Seierstad's work is presented in a feature article published on the home page of Helse Sør-Øst.
An article by senior scientist Lene Malerød and her co-workers in Kaisa Haglund’s project group shows how the mitotic spindle achieves its correct orientation during cell division.
The article ”Centrosomal ALIX regulates mitotic spindle orientation by modulating astral microtubule dynamics” was published online on June 1 in The EMBO Journal and elucidates a previously unrecognized biological role of the multifunctional adaptor protein ALIX during cell division. Specifically, ALIX is recruited to centrosomes, where it promotes correct mitotic spindle orientation at metaphase during both asymmetric and symmetric cell division, by facilitating the formation of astral microtubules.
WiBEC (Wireless In-Body Environment Communications) is a Horizon 2020 Marie Skłodowska-Curie Innovative Training Network and trains 16 young researchers in coordinated manner by academia, industry and medical centres. WiBEC is led by Professor Ilangko Balasingham at the Intervention Centre at Oslo University Hospital.
WiBEC has been identified by the Innovation Radar - a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation framework programmes.
WiBEC’s main objective is to provide high quality and innovative doctoral training to develop the wireless technologies for novel implantable devices that will contribute to the improvement in quality and efficacy of healthcare. These are innovations that are actively exploring value creation opportunities and rated by the European Commission as Excellent Science.
The BETAMI trial - "BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function" - has been funded with 15 mill NOK from Klinbeforsk - the national "Clinical therapy research in the specialist health services" program. The trial is led by Dan Atar, head of research at the Division of Medicine and leader of the "Ischemic Heart Disease" group. In the 80's and 90's it was considered important to administer beta blockers to avoid future cardiac deaths and new heart attacks. "But huge progress has been made, among other things, the blockage of blood vessels is very effective. We do not know if beta-blocking is still necessary", says Atar, who has recently been interviewed by "Dagens Medisin".